Your browser doesn't support javascript.
loading
Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials.
Sen, S; Carmagnani Pestana, R; Hess, K; Viola, G M; Subbiah, V.
Affiliation
  • Sen S; Sarah Canon Research Institute at HealthONE, Denver, USA.
  • Carmagnani Pestana R; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Hess K; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Viola GM; Department of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: vsubbiah@mdanderson.org.
Ann Oncol ; 29(12): 2396-2398, 2018 12 01.
Article in En | MEDLINE | ID: mdl-30307530
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gastrointestinal Microbiome / Antineoplastic Agents, Immunological / Anti-Bacterial Agents / Neoplasms Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2018 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gastrointestinal Microbiome / Antineoplastic Agents, Immunological / Anti-Bacterial Agents / Neoplasms Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2018 Document type: Article Affiliation country: Country of publication: